Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407716 · ClinicalTrials.gov registry record · Early Phase 1
Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03407716: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03407716 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03407716, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG American Ginseng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-02-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03407716
The ClinicalTrials.gov registry entry for NCT03407716 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03407716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03407716 about?
NCT03407716 is a clinical study titled "Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors". This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.
What is the current status of trial NCT03407716?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2019-03-01. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT03407716?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), American Ginseng (DRUG).
Who is sponsoring clinical trial NCT03407716?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.